Artificial intelligence in transfusion medicine: Promise, pragmatism, and the path forward

Artificial intelligence (AI) has moved rapidly from buzzword to infrastructure.1 In pathology and laboratory medicine, algorithms now read slides, parse genomes, and predict sepsis before the first vasopressor hangs.2-6 Yet transfusion medicine — a discipline that generates rich, longitudinal data linking the donor, the product, and the recipient — has remained largely manual in its analytic mindset. That gap is both a vulnerability and an opportunity. As hospitals face mounting financial pressure, staff shortages, and demands for traceable quality, transfusion services stand to gain from the same analytic precision that has transformed imaging and microbiology. The challenge is to integrate AI tools without compromising the safety, equity, and human judgment that define our field. This commentary outlines where AI could meaningfully improve transfusion practice and what guardrails must be in place to ensure responsible adoption. Few areas are better suited for AI-driven support than patient blood management (PBM). Traditional transfusion thresholds — fixed numeric cutoffs — ignore context.7-10 An algorithmic approach could incorporate vital signs, laboratory trends, comorbidities, and procedural risk to suggest individualized transfusion triggers. Similarly, preoperative anemia pathways are ripe for automation. Machine learning models can flag candidates for iron or erythropoiesis-stimulating therapy, track whether interventions were ordered, and nudge clinicians before surgery.11-13 Such “closed-loop” optimization ensures patients enter the operating room with the best possible hematologic reserve.14, 15 Future calculators could extend beyond decision thresholds to dosing itself. As direct total blood volume (TBV) or lean body mass (LBM) measurement devices become clinically available,16-18 AI-enhanced “right product, right dose” tools could personalize transfusion volumes more precisely than the standard “one-unit” increment. The central principle is augmentation, not automation: decision support that surfaces context, leaving the transfusion physician as the final arbiter. Supply chain optimization is already a proving ground for AI in other industries.19 In transfusion medicine, where platelets expire within days and demand is inherently stochastic, predictive modeling could be transformative. AI systems can forecast demand at the service line and even day-of-week level, using historical transfusion data, scheduled procedures, and local events.20-24 Hospitals could adjust standing orders accordingly, balancing safety margins with waste reduction. Algorithms could also enable “expiry-aware” redistribution, automatically identifying which units are approaching outdate and suggesting transfers to high-use sites. Donor recruitment may similarly benefit: blood centers could use predictive analytics to target under-represented phenotypes or blood types, focusing outreach where shortages are most likely to emerge. Such applications align AI's strengths — pattern recognition and dynamic adjustment — with transfusion medicine's operational imperatives. AI's potential extends beyond logistics to the interpretive heart of transfusion medicine. Serologic pattern recognition is one of the most time-consuming and expertise-dependent processes in the laboratory. Machine learning models trained on large libraries of antibody panels could suggest rule-in/rule-out probabilities, flag inconsistencies, and recommend next steps — such as enzyme treatment, dithiothreitol (DTT), or adsorption — using explainable logic derived from expert practice.25-27 Computer vision adds another dimension. Image-based agglutination grading for direct antiglobulin tests or tube/card assays could standardize interpretation, reducing interobserver variability. On the hemovigilance front, natural language processing (NLP) can scan nursing notes and vital-sign trends to flag suspected transfusion reactions in real time.28-33 Algorithms trained on labeled datasets might detect clusters suggestive of TRALI, TACO, or bacterial contamination earlier than manual review. Automated prompts could ensure follow-up cultures, BNP testing, or post-transfusion labs are completed, closing the safety loop. Each of these functions addresses a longstanding bottleneck: identifying significant signals amid routine noise. Therapeutic apheresis sits at the intersection of physiology, fluid dynamics, and logistics, making it an ideal test bed for predictive modeling. AI-enabled planning tools could personalize exchange volumes based on measured rather than estimated TBV,16-18 hematocrit, and device parameters, optimizing the number of cycles while minimizing citrate toxicity.34, 35 Beyond efficiency, predictive algorithms could serve a safety role by forecasting adverse events such as hypotension, allergic reactions, or later bleeding, enabling preemptive monitoring and supportive measures. At the service level, optimization algorithms could balance nurse assignments, device availability, and room scheduling, smoothing daily operations without overtaxing staff. These applications demonstrate AI's potential not to replace expertise but to multiply its reach. Component manufacturing generates continuous process data — centrifuge speeds, spin profiles, temperature curves, gas exchange rates — that is rarely analyzed in aggregate. AI excels in this domain. Anomaly detection models can flag deviations from expected process signatures, enabling early intervention before out-of-spec products occur.36, 37 Predictive maintenance can identify equipment trending toward failure, and statistical drift analysis of QC metrics can reveal subtle shifts in pH or hemolysis trends.38-40 This proactive quality assurance approach could reduce waste, improve compliance, and enhance product consistency: key outcomes in an increasingly regulated environment. Not every high-impact use case is clinical. Generative AI can relieve the administrative burden that erodes time for patient care and teaching. Draft transfusion reaction notes, product utilization summaries, or discharge instructions can be auto-generated for clinician edit, improving documentation completeness without reducing accountability.41, 42 Educational applications are equally promising. De-identified local data could be transformed into synthetic teaching cases for residents, offering realistic exposure to institutional patterns without privacy risk.43-45 As transfusion medicine strives to attract new learners, such tools could broaden engagement while preserving data security. Every algorithm touching patient care must meet the same standards as laboratory-developed tests: rigorous validation, version control, and continuous performance monitoring.46 CLIA and CAP frameworks can be adapted to algorithmic tools, keeping them squarely in the category of decision support rather than autonomous decision-making. Clinicians must be able to understand why a model recommends a course of action. Transparent outputs, audit trails, and versioned updates are nonnegotiable. Without interpretability, trust and adoption will falter. AI systems are only as fair as the data used to train them.47-49 Demographic imbalances in transfusion datasets, whether by sex, race, or disease group, can propagate inequities. Routine auditing for differential performance and clear escalation pathways for correction are essential. Transfusion data contain sensitive donor and recipient information. Responsible AI development requires minimal use of PHI, secure machine learning operations, and adherence to IRB or QI pathways. Institutions must treat data stewardship as a professional obligation, not a compliance formality. AI should assist, never replace, the judgment of transfusion medicine professionals. Human oversight is the ultimate safety mechanism and ethical safeguard. Transfusion medicine has always balanced innovation with vigilance. The field pioneered quality assurance before “quality” became a healthcare buzzword and developed massive databases before “big data” was coined. That same discipline positions us to lead AI integration responsibly. The most immediate gains will come not from glamorous algorithms but from targeted, validated tools that reduce cognitive load, improve safety, and support stewardship. Pathologists, transfusion specialists, and apheresis physicians should view AI not as a threat to expertise but as a force multiplier for it. Our challenge is to stay engaged: defining use cases, shaping validation standards, and ensuring that compassion and context remain central. When done well, AI will not replace the human intelligence at the heart of transfusion medicine. It will reflect it back to us, sharper and more scalable. ChatGPT (OpenAI, San Francisco, CA) was used to assist in drafting and revising portions of this commentary under the direct supervision of the author. The author reviewed, edited, and approved all text to ensure accuracy, originality, and appropriate interpretation. No data, analysis, or conclusions were generated by the model. The author has disclosed no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.